KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

KRAS mutations are a predictor of resistance to cetuximab therapy and are associated with a worse prognosis, and the EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment.